SQZ Biotech
134 Coolidge Ave
Second Floor
Watertown
MA
02472
United States
Tel: (603) 490-9117
Website: http://sqzbiotech.com/
84 articles about SQZ Biotech
-
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
8/10/2023
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies, reported second quarter 2023 financial results and recent portfolio updates.
-
SQZ Biotechnologies Provides Update on Collaboration with Roche
7/25/2023
SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced that Roche has determined that it will not exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program.
-
Embattled SQZ Biotechnologies announced Tuesday that the Swiss biotech will not exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program.
-
NYSE to Commence Delisting Proceedings Against SQZ Biotechnologies Company (SQZ)
7/3/2023
The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of SQZ Biotechnologies Company — ticker symbol SQZ — from the NYSE.
-
SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split
6/15/2023
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies, announced that its Board of Directors has approved a 1-for-10 reverse stock split of its common stock, par value $0.001 per share, that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time.
-
SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates
5/10/2023
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies, reported first quarter 2023 financial results and recent portfolio updates.
-
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
1/18/2023
SQZ Biotechnologies announced that on January 18, 2023, it received notice from the New York Stock Exchange indicating that the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period.
-
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors
12/6/2022
SQZ Biotechnologies Company (NYSE: SQZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s Enhanced Antigen Presenting Cell (eAPC) candidate for the treatment of HPV16+ advanced or metastatic solid tumors.
-
SQZ Biotechnologies is slashing 60% of its workforce and looking for a new CEO after initiating a strategic prioritization to focus on its cell therapy platform for solid tumors.
-
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer
11/30/2022
SQZ Biotechnologies (NYSE: SQZ) today announced the strategic prioritization of its clinical portfolio to concentrate on the development of its second-generation enhanced Antigen Presenting Cells (eAPC) cell therapy program, focused on HPV16 positive recurrent, locally advanced, or metastatic solid tumors.
-
SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting
11/10/2022
SQZ Biotechnologies Presents Cell Squeeze ® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting.
-
SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates
11/9/2022
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported third quarter 2022 financial results and recent portfolio updates.
-
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy
10/3/2022
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced the publication of preclinical research on the SQZ® Activating Antigen Carrier platform.
-
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies
9/12/2022
SQZ Biotechnologies Company today presented preclinical data supporting that tumor infiltrating lymphocytes (TILs) engineered with membrane-bound cytokines IL-2 (mbIL-2) and IL-12 (mbIL-12) may eliminate the need for the high-dose, systemic IL-2 and lymphodepleting preconditioning used with current TIL therapies.
-
SQZ Biotechnologies to Present at Upcoming September 2022 Investor Conferences
9/7/2022
SQZ Biotechnologies Company announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder at SQZ Biotechnologies, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 and at the Chardan 6th Annual Genetic Medicines Conference on October 4.
-
SQZ Biotechnologies Announces Leadership Transition
9/6/2022
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that Howard Bernstein, M.D., Ph.D., has been appointed to the company’s board of directors, effective October 31, 2022.
-
SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
8/4/2022
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2022 financial results and recent portfolio updates.
-
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
7/11/2022
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Micah Zajic, as the company’s Chief Financial Officer, effective immediately.
-
The Roche Accelerator is designed to help companies bridge the gap between idea and proof-of-concept. It is one of several incubators recently founded by Western companies.
-
SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
6/21/2022
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, presented Tolerizing Antigen Carrier nonclinical results at the 2022 Federation of Clinical Immunology Sciences annual meeting.